Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 630

1.

A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma.

Liu N, Cui RX, Sun Y, Guo R, Mao YP, Tang LL, Jiang W, Liu X, Cheng YK, He QM, Cho WC, Liu LZ, Li L, Ma J.

Int J Cancer. 2014 Mar 15;134(6):1359-68. doi: 10.1002/ijc.28468. Epub 2013 Sep 30.

2.

Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.

Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY, Ma J.

Lancet Oncol. 2012 Jun;13(6):633-41. doi: 10.1016/S1470-2045(12)70102-X. Epub 2012 May 3.

PMID:
22560814
3.

Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients.

Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G, Maciejewski R.

Int J Cancer. 2013 Apr 1;132(7):1633-45. doi: 10.1002/ijc.27840. Epub 2012 Oct 17.

4.

Profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing.

Wang HY, Yan LX, Shao Q, Fu S, Zhang ZC, Ye W, Zeng YX, Shao JY.

Clin Chem. 2014 May;60(5):773-82. doi: 10.1373/clinchem.2013.214213. Epub 2014 Feb 21.

5.
6.

miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.

Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ.

J Thorac Oncol. 2011 Mar;6(3):482-8. doi: 10.1097/JTO.0b013e318208c785.

7.

Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer.

Jiang X, Du L, Wang L, Li J, Liu Y, Zheng G, Qu A, Zhang X, Pan H, Yang Y, Wang C.

Int J Cancer. 2015 Feb 15;136(4):854-62. doi: 10.1002/ijc.29041. Epub 2014 Jul 1.

8.

Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.

Zhang G, Zong J, Lin S, Verhoeven RJ, Tong S, Chen Y, Ji M, Cheng W, Tsao SW, Lung M, Pan J, Chen H.

Int J Cancer. 2015 Mar 1;136(5):E301-12. doi: 10.1002/ijc.29206. Epub 2014 Sep 18.

9.

Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.

Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A.

Ann Surg. 2014 Apr;259(4):735-43. doi: 10.1097/SLA.0b013e3182a6909d.

10.

Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH.

Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24239208
11.

MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.

Heinzelmann J, Unrein A, Wickmann U, Baumgart S, Stapf M, Szendroi A, Grimm MO, Gajda MR, Wunderlich H, Junker K.

Ann Surg Oncol. 2014 Mar;21(3):1046-54. doi: 10.1245/s10434-013-3361-3. Epub 2013 Nov 18.

PMID:
24242678
12.

Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer.

Liu X, Zhang X, Zhang Z, Chang J, Wang Z, Wu Z, Wang C, Sun Z, Ge X, Geng R, Tang W, Dai C, Lin Y, Lin F, Sun M, Jia W, Xue W, Ji J, Hu Y, Qin G, Li J.

Int J Cancer. 2017 Nov 15;141(10):2093-2102. doi: 10.1002/ijc.30895. Epub 2017 Jul 28.

PMID:
28722210
13.

Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.

Hur K, Toiyama Y, Schetter AJ, Okugawa Y, Harris CC, Boland CR, Goel A.

J Natl Cancer Inst. 2015 Feb 6;107(3). pii: dju492. doi: 10.1093/jnci/dju492. Print 2015 Mar.

14.

miR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma.

Luo Z, Dai Y, Zhang L, Jiang C, Li Z, Yang J, McCarthy JB, She X, Zhang W, Ma J, Xiong W, Wu M, Lu J, Li X, Li X, Xiang J, Li G.

Carcinogenesis. 2013 Feb;34(2):415-25. doi: 10.1093/carcin/bgs329. Epub 2012 Oct 24.

PMID:
23097559
15.

microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.

Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B, Amsellem-Ouazana D, Bieche I.

Int J Cancer. 2013 Jun 1;132(11):2479-91. doi: 10.1002/ijc.27949. Epub 2013 Feb 25.

16.

MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma.

Feber A, Xi L, Pennathur A, Gooding WE, Bandla S, Wu M, Luketich JD, Godfrey TE, Litle VR.

Ann Thorac Surg. 2011 May;91(5):1523-30. doi: 10.1016/j.athoracsur.2011.01.056. Epub 2011 Mar 21.

17.

microRNA expression profiling of nasopharyngeal carcinoma.

Li T, Chen JX, Fu XP, Yang S, Zhang Z, Chen KhH, Li Y.

Oncol Rep. 2011 May;25(5):1353-63. doi: 10.3892/or.2011.1204. Epub 2011 Mar 3.

PMID:
21373758
18.

Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H.

J Clin Oncol. 2010 Apr 1;28(10):1721-6. doi: 10.1200/JCO.2009.24.9342. Epub 2010 Mar 1.

PMID:
20194856
19.

Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.

Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, Ditzel HJ.

Mol Oncol. 2014 Jul;8(5):874-83. doi: 10.1016/j.molonc.2014.03.002. Epub 2014 Mar 16.

20.

Methods and matrices: approaches to identifying miRNAs for nasopharyngeal carcinoma.

Plieskatt JL, Rinaldi G, Feng Y, Levine PH, Easley S, Martinez E, Hashmi S, Sadeghi N, Brindley PJ, Bethony JM, Mulvenna JP.

J Transl Med. 2014 Jan 6;12:3. doi: 10.1186/1479-5876-12-3.

Supplemental Content

Support Center